不同人参皂苷单体对鼻咽癌放疗患者外周血淋巴细胞的体外免疫增强作用

发布时间：2018-04-18 10:34

  本文选题：人参皂苷 + 鼻咽癌　； 参考：《安徽医科大学》2015年硕士论文

【摘要】：目的放疗是鼻咽癌患者治疗的首选方案,但放疗在杀伤肿瘤细胞的同时也会对机体免疫功能造成损伤。人参皂苷(ginsenosidess,GS)作为人参的主要有效成分具有显著的免疫增强作用。本研究分别采用人参皂苷单体Rg3、Rg1、Rb1体外刺激鼻咽癌放疗患者外周血淋巴细胞,旨在探讨不同人参皂苷体外对鼻咽癌放疗患者外周血淋巴细胞的免疫调节作用及其机制。方法选取鼻咽癌并接受放疗患者共100例为研究对象,按随机数字表法分为Control组、Rg3组、Rg1组、Rb1组,每组25例。放疗结束后,分离各组患者外周血淋巴细胞。按分组不同加入不同刺激物,Control组分别加入终浓度为1mg/L、10mg/L、100mg/L的DMSO,Rg3组分别加入终浓度为1mg/L、10mg/L、100mg/L的人参皂苷单体Rg3,Rg1组分别加入终浓度为1mg/L、10mg/L、100mg/L的人参皂苷单体Rg1、Rb1组分别加入终浓度为1mg/L、10mg/L、100mg/L的人参皂苷单体Rb1。采用MTT法检测淋巴细胞增殖,流式细胞仪检测淋巴细胞亚群及膜表面分子表达,间接ELISA法检测Ig G、Ig M抗体水平及Th1/Th2细胞因子表达。结果:(1)人参皂苷单体Rg3、Rg1、Rb1处理鼻咽癌放疗患者外周血淋巴细胞72h后,可显著促进Con A及LPS诱导的淋巴细胞增殖,与Control组比较差异具有统计学意义(P0.05),且呈显著剂量依赖性;Rg3组促淋巴细胞增殖作用显著优于Rg1组和Rb1组(P0.05);Rg1组与Rb1组比较差异无统计学意义(P0.05)。(2)人参皂苷单体Rg3、Rg1、Rb1处理鼻咽癌放疗患者外周血淋巴细胞72h后,可显著上调淋巴细胞亚群CD4+比例、CD4+/CD8+比值,同时显著下调CD8+比例,与Control组比较差异具有统计学意义(P0.05),且呈显著剂量依赖性;Rg3组作用显著优于Rg1组和Rb1组(P0.05);Rg1组与Rb1组比较差异无统计学意义(P0.05)。(3)人参皂苷单体Rg3、Rg1、Rb1处理鼻咽癌放疗患者外周血淋巴细胞72h后,可显著上调外周血T淋巴细胞表面CD3+/HLA-DR+和B细胞表面CD19+/CD69+表达水平,与Control组比较差异具有统计学意义(P0.05),且呈显著剂量依赖性;Rg3组作用显著优于Rg1组和Rb1组(P0.05);Rg1组与Rb1组比较差异无统计学意义(P0.05)。(4)人参皂苷单体Rg3、Rg1、Rb1处理鼻咽癌放疗患者外周血淋巴细胞72h后,可显著促进外周血淋巴细胞Ig G、Ig M抗体分泌,与Control组比较差异具有统计学意义(P0.05),且呈显著剂量依赖性;Rg3组作用显著优于Rg1组和Rb1组(P0.05);Rg1组与Rb1组比较差异无统计学意义(P0.05)。(5)人参皂苷单体Rg3、Rg1、Rb1处理鼻咽癌放疗患者外周血淋巴细胞72h后,可显著上调外周血淋巴细胞IL-2表达,同时下调IL-6表达,与Control组比较差异具有统计学意义(P0.05),且呈显著剂量依赖性;Rg3组作用显著优于Rg1组和Rb1组(P0.05);Rg1组与Rb1组比较差异无统计学意义(P0.05)。结论:人参皂苷Rg3、Rg1、Rb1可显著增强鼻咽癌放疗患者外周血淋巴细胞增殖能力、抗原递呈能力,纠正放疗所致淋巴细胞亚群比例失衡及Th1/Th2免疫漂移,提高机体Ig G、Ig M抗体水平,且Rg3作用显著优于Rg1及Rb1。提示人参皂苷Rg3、Rg1、Rb1可作为免疫增强剂潜在性的拮抗鼻咽癌放疗所致的免疫抑制。
[Abstract]:Radiotherapy is the preferred solution to treatment of nasopharyngeal carcinoma, but the radiation would damage the immune function in tumor cells at the same time. Ginsenoside (ginsenosidess, GS) as the main active ingredient of ginseng has significantly enhanced the immunity. This study were collected by ginsenoside Rg3, Rg1, Rb1 were stimulated in vitro radiotherapy of peripheral blood lymphocytes, immune was to investigate the effects of Ginsenoside in vitro on nasopharyngeal carcinoma patients peripheral blood lymphocyte regulation and its mechanism. Methods the nasopharyngeal carcinoma radiotherapy and 100 patients as the research object, randomly divided into Control group, Rg3 group, Rg1 group, Rb1 group, 25 cases in each group at the end of radiotherapy, peripheral blood lymphocytes were separated from patients with different. By grouping with different stimuli, group Control as the concentration of 1mg/L, 10mg/L, 100mg/L, DMSO, Rg3 group As the concentration of 1mg/L, 10mg/L, ginsenoside Rg3 100mg/L, group Rg1 as the concentration of 1mg/L, 10mg/L, ginsenoside Rg1 100mg/L, group Rb1 as the concentration of 1mg/L, 10mg/L, ginsenoside Rb1. 100mg/L MTT method was used to detect the expression of lymphocyte proliferation, flow cytometry cells detected by lymphocyte subsets and membrane surface molecules, detection of Ig G by indirect ELISA, the antibody level of M expression of Ig and Th1/Th2 cytokines. Results: (1) ginsenoside Rg3, Rg1, Rb1 in patients with nasopharyngeal carcinoma after radiotherapy of peripheral blood lymphocytes after 72h, Con and A can significantly promote LPS induced the lymphocyte proliferation, compared with the Control group. The difference was statistically significant (P0.05), and a significant dose dependence; group Rg3 lymphocyte proliferation was significantly higher than Rg1 group and Rb1 group (P0.05); there was no significant difference between Rg1 group and Rb1 group (P0.05) (2 people). Ginsenoside monomer Rg3, Rg1, 72h lymphocytes in peripheral blood of patients with nasopharyngeal carcinoma after Rb1, significantly increased the proportion of CD4+ lymphocyte subsets, CD4+/CD8+ ratio, and significantly reduced the proportion of CD8+, compared with Control group. The difference was statistically significant (P0.05), and a significant dose dependence; effect of Rg3 group was higher than that of Rg1 group and the Rb1 group (P0.05); there was no significant difference between Rg1 group and Rb1 group (P0.05). (3) ginsenoside Rg3, Rg1, 72h lymphocytes in peripheral blood of patients with nasopharyngeal carcinoma after Rb1 significantly increased peripheral blood T lymphocyte cell surface CD3+/HLA-DR+ and B cell surface expression of CD19+/CD69+. Compared with the Control group. The difference was statistically significant (P0.05), and showed a significant dose-dependent effect; Rg3 group was significantly higher than Rg1 group and Rb1 group (P0.05); the difference between the Rg1 group and Rb1 group had no statistical significance (P0.05). (4) ginsenoside Rg3, Rg1, Rb1 72h of peripheral blood lymphocytes in patients with nasopharyngeal carcinoma after radiotherapy treatment, can significantly promote peripheral blood lymphocyte Ig G, Ig M antibody secretion, compared with the Control group. The difference was statistically significant (P0.05), and showed a significant dose-dependent effect; Rg3 group was significantly higher than Rg1 group and Rb1 group (P0.05); no significant difference Rg1 group and Rb1 group (P0.05). (5) ginsenoside Rg3, Rg1, 72h lymphocytes in peripheral blood of patients with nasopharyngeal carcinoma after Rb1, IL-2 expression was significantly up-regulated in peripheral blood lymphocytes, and down-regulation of IL-6 expression, compared with the Control group the difference was statistically significant (P0.05), and a significant dose dependent; effect of Rg3 group was significantly higher than Rg1 group and Rb1 group (P0.05); there was no significant difference between Rg1 group and Rb1 group (P0.05). Conclusion: ginsenoside Rg3, Rg1, Rb1 can significantly enhance the radiotherapy of nasopharyngeal carcinoma patients with peripheral blood lymphocyte proliferation, antigen presentation to Correct, radiotherapy lymphocyte subsets imbalance and immune Th1/Th2 drift, improve the body of Ig G, Ig M antibody level was significantly better than that of Rg1 and Rg3 and Rb1. suggest that ginsenoside Rg3, Rg1, Rb1 can be used as immune enhancement caused by antagonistic potential of nasopharyngeal carcinoma radiotherapy agent immunosuppression.

【学位授予单位】：安徽医科大学
【学位级别】：硕士
【学位授予年份】：2015
【分类号】：R739.63

【参考文献】

相关期刊论文 前10条

1 梅少林;袁红艳;曹湘博;常雅萍;李平亚;刘金萍;;人参皂苷Rg3对HSE模型鼠的治疗作用及免疫调节效应[J];吉林大学学报(医学版);2007年01期

2 张锐;徐华丽;于小风;曲绍春;陈明侠;睢大员;;20(S)-原人参二醇对荷瘤裸鼠化疗的增效减毒作用[J];吉林大学学报(医学版);2009年02期

3 邱雪;洪铁;孟勤;杨振;吕惠子;;人参皂苷单体Rb_1、Re及Rg_1对肾上腺素所致小鼠耳廓微循环障碍的改善作用[J];吉林大学学报(医学版);2009年02期

4 刘伟宏，龚守良，李新民，刘树铮;人参三醇组甙对雄性大鼠免疫器官的辐射防护作用[J];白求恩医科大学学报;1994年01期

5 马德慧;薛江东;姚春雨;孟宪龙;杨明霞;刘国文;;H5N2亚型禽流感病毒中药佐剂灭活苗对公雏鸡外周血T淋巴细胞亚群的影响[J];中国畜牧兽医;2009年09期

6 Marlinda Adham;Antonius N.Kurniawan;Arina Ika Muhtadi;Averdi Roezin;Bambang Hermani;Soehartati Gondhowiardjo;I Bing Tan;Jaap M.Middeldorp;;Nasopharyngeal carcinoma in Indonesia:epidemiology,incidence,signs,and symptoms at presentation[J];癌症;2012年04期

7 史秀山;人参皂苷Rb1提高狂犬病疫苗免疫效果的研究[J];中国热带医学;2005年01期

8 毛平;马骏;陈艳艳;虞桂珍;谭梦晖;;不同药性补气中药对小鼠脾淋巴细胞增殖及细胞因子分泌的影响[J];上海中医药大学学报;2006年03期

9 陈曜;陈春山;;人参皂甙小分子的生物学作用[J];临床和实验医学杂志;2010年21期

10 田志刚,刘杰,孙lm,李柏青,张捷,张建华;人参三醇型皂甙对IL-6基因的促转录效应[J];中国药理学通报;1993年05期

相关博士学位论文 前1条

1 宋晓明;不同来源人参皂甙免疫佐剂作用的研究[D];浙江大学;2009年

相关硕士学位论文 前1条

1 解慧梅;黄芪多糖、人参皂甙Rb1对猪口蹄疫疫苗的佐剂效果及相关机理研究[D];河北农业大学;2006年

，

本文编号：1767993